Keenova Therapeutics plc reports company news around its branded therapeutics portfolio for rare and unaddressed conditions. Recurring updates cover financial results, clinical publications, disease-awareness campaigns, and presentations involving products and programs such as Acthar Gel, XIAFLEX, TERLIVAZ, and collagenase clostridium histolyticum research.
The company's communications emphasize specialty therapeutic areas that include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. News also covers integration activity following its business combination, U.S. manufacturing operations, and portfolio performance drivers across established branded medicines.
Mallinckrodt presented data on TERLIVAZ® (terlipressin) for treating hepatorenal syndrome (HRS) at the 2024 Digestive Disease Week in Washington, DC. The presentations included a post-hoc analysis from the Phase III CONFIRM trial and a pooled analysis of three Phase III studies. The results indicate that TERLIVAZ is effective in improving kidney function in patients with HRS-AKI, even with dose interruptions, and is particularly beneficial for patients with baseline serum creatinine (SCr) levels below 5 mg/dL. TERLIVAZ is the first FDA-approved treatment for HRS with rapid kidney function decline, impacting over 42,000 Americans annually. The safety profile includes risks of serious respiratory failure and ischemic events, and the treatment is not recommended for certain high-risk patients.
Mallinckrodt plc reported first quarter 2024 financial results with net sales of $467.8 million, showing 10.2% year-over-year growth. The company achieved a net loss of $65.4 million, reflecting a 73.8% improvement, and delivered adjusted EBITDA of $144.9 million, up by 17.3% year-over-year. Mallinckrodt also initiated the rollout of INOmax EVOLVE DS Delivery System and anticipates the launch of Acthar Gel SelfJect Injector in the third quarter of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.